Valuation
- Market cap
- 2,423,301,000
- Revenue TTM
- $1,395,130,000
- Net income TTM
- $977,290,000
- PE ratio
- 5.72
- Forward PE
- 9.45
- Profit margin
- 70.05%
- Debt to equity
- 0.02
Trading
- Volume
- 100
- Avg volume
- 1,384
- Day's range
- $33.88 – $33.88
- Shares out
- 71,526,000
- Stochastic %K
- 11%
- Beta
- 0.95
- Analysts
- Sell
- Price target
- $420.00
Company profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypogl...
Show more
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 45 88 77 36 00
- Website
- https://www.zealandpharma.com
- Address
- Sydmarken 11, Søborg, Denmark
Latest news
No headlines yet.
